BIOGEN INC (BIIB) Stock Price, Quote, News and Overview
NASDAQ:BIIB - Nasdaq - US09062X1037 - Common Stock
BIIB Quote and Key Statistics
BIOGEN INC
NASDAQ:BIIB (1/22/2025, 5:20:02 PM)
After market: 142.75 0 (0%)142.75
+1.77 (+1.26%)
BIIB Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.81% | ||
| ROA | 5.7% | ||
| ROE | 9.87% | ||
| Debt/Equity | 0.28 |
BIIB Performance and Technical Analysis
BIIB Ownership and Analysts
BIIB Latest News and Analysis
Tuesday's session: top gainers and losers in the S&P500 index
Top S&P500 movers in Tuesday's session
Which S&P500 stocks are moving on Tuesday?
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
Gapping S&P500 stocks in Tuesday's session
Tuesday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.
Interesting BIIB Put And Call Options For March 21st
Notable Thursday Option Activity: BYND, BIIB, MUSA
About BIIB
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,570 full-time employees. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. The company also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. The company commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.
Company Info
BIOGEN INC
225 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Michel Vounatsos
Employees: 7570
Company Website: https://www.biogen.com/
Investor Relations: https://investors.biogen.com
Phone: 17814642000
BIIB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.74 | 299.00B | ||
| AMGN | AMGEN INC | 14.23 | 146.98B | ||
| GILD | GILEAD SCIENCES INC | 21 | 115.95B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839.22 | 110.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.97 | 74.73B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.38B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.75B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.66B | ||
| NTRA | NATERA INC | N/A | 22.70B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.34B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.31 | 16.57B |